Skip to main content

Advertisement

SpringerLink
Log in

Research Deviations in FDA-Regulated Clinical Trials: A Cross-Sectional Analysis of FDA Inspection Citations

  • Clinical Trials: Original Research
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

Background

The US Food and Drug Administration (FDA) ensures clinical trials meet regulatory/ethical standards through inspections. If FDA Investigators observe potential violations of regulatory requirements during an inspection, a firm will receive a Form FDA 483, Inspectional Observations. Violations cited have resulted in the death of human research subjects, prosecution of research personnel, and denial of approval for new medical products. Objectives included the standardization of Violation Themes cited for analysis by inspection firm type, geographic location, and Violation Theme citation to provide insight into regulatory violations.

Methods

Cross-sectional analysis of citations published in public databases between October 1, 2005, and September 30, 2015, by the FDA for inspections under the Bioresearch Monitoring program. For each inspection citation, the main measure was the Code of Federal Regulation cited coded into a standardized Violation Theme for citation analysis.

Results

Under the Bioresearch Monitoring program, 3281 inspections received a Form FDA 483 in 2007-2015. FDA inspections have increased over this period but the rate of Form FDA 483 issuance has decreased. On average, Sponsor-Investigators received 4.41 citations per inspection compared to clinical researchers alone receiving 2.21. One-third of violations were related to adherence to investigational procedures followed by informed consent and study records issues.

Conclusions

In the last decade, the number of violations observed under the Bioresearch Monitoring program has decreased; however, significant improvements can still be made regarding adherence to study procedures, the consenting of human research subjects, and creation of adequate and accurate study documentation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fillon M. Two federal agencies tighten rules for clinical trials. J Natl Cancer Inst. 2016;108:djw309.

    Article  Google Scholar 

  2. US National Library of Medicine, US National Institutes of Health. Trends, charts, and maps. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/resources/trends#RegisteredStudiesOverTime. Published April 27, 2017. Accessed April 30, 2017.

  3. Shetty YC, Saiyed AA. Analysis of warning leters issued by the US Food and Drug Administration to researchers, institutional review boards and sponsors: a retrospective study. J Med Ethics. 2014;41:398–403.

    Article  Google Scholar 

  4. Morgan-Linnell SK, Stewart DJ, Kurzrock R. US Food and Drug Administration inspections of clinical investigators: overview of results from 1977 to 2009. Clin Cancer Res. 2014;20:3364–3370.

    Article  Google Scholar 

  5. Kelsey FO. The Bioresearch Monitoring Program. Food Drug Cosmetic Law J. 1991;46:59–64.

    Google Scholar 

  6. US Food and Drug Administration. Kefauver-Harris Amendments revolutionized drug development. US Food and Drug Administration. https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm322856.htm. Published March 20, 2017. Accessed April 30, 2017.

  7. Office of Good Clinical Practice, Office of Special Medical Programs, Office of the Commissioner, US Food and Drug Administration. Information sheet: Guidance for IRBs, clinical investigators, and sponsors: FDA inspections of clinical investigators. US Food and Drug Administration. https://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126553.pdf. Published June 2010. Accessed April 30, 2017.

  8. US Food and Drug Administration. Compliance Program 7348.811 Chapter 48: Bioresearch Monitoring: Researchers and Sponsor-Investigators. US Food and Drug Administration. http://www.fda.gov/downloads/ICECI/EnforcementActions/BioresearchMonitoring/ucm133773.pdf. Published December 8, 2008. Accessed April 30, 2017.

  9. Center for Tobacco, US Food and Drug Administration. Building on six years of accomplishments in tobacco. US Food and Drug Administration. https://www.fda.gov/downloads/TobaccoProducts/NewsEvents/UCM484167.pdf. Published July 2015. Accepted April 30, 2017.

  10. DeMarinis AJ. FDA GCP/BIMO inspections: what, why, and how? Res Pract. 2012;13:20–31.

    Google Scholar 

  11. DeMarinis AJ. What to expect during an FDA Good Clinical Practice/Bioresearch Monitoring inspection. Res Pract. 2015;16:87–94.

    Google Scholar 

  12. US Food and Drug Administration. Inspection observations. US Food and Drug Administration. https://www.fda.gov/ICECI/Inspections/ucm250720.htm. Published January 24, 2017. Accessed April 30, 2017.

  13. Huit WM. FDA Form 483: minimizing FDA inspection citations. Chem Eng. 2014;121:48–53.

    Google Scholar 

  14. US Food and Drug Administration. ORA Vision & Mission. US Food and Drug Administration. https://www.fda.gov/AboutFDA/CentersOffices/OfficeofGlobalRegulatoryOperationsandPolicy/ORA/ucm135281.htm. Published August 11, 2014. Accessed April 30, 2017.

  15. US Food and Drug Administration. Bioresearch Monitoring (BIMO) Metrics—FY’07. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RunningClinicalTrials/UCM261827.pdf. Accessed April 26, 2016.

  16. US Food and Drug Administration. Bioresearch Monitoring (BIMO) Metrics—FY’08. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RunningClinicalTrials/UCM261840.pdf. Accessed April 26, 2016.

  17. US Food and Drug Administration. Bioresearch Monitoring (BIMO) Metrics—FY’09. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RunningClinicalTrials/UCM261846.pdf. Accessed April 26, 2016.

  18. US Food and Drug Administration. Bioresearch Monitoring (BIMO) Metrics—FY’10. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RunningClinicalTrials/UCM261855.pdf. Accessed April 26, 2016.

  19. US Food and Drug Administration. Bioresearch Monitoring (BIMO) Metrics—FY’11. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RunningClinicalTrials/UCM296250.pdf. Accessed April 26, 2016.

  20. US Food and Drug Administration. Bioresearch Monitoring (BIMO) Metrics—FY’12. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RunningClinicalTrials/UCM341516.pdf. Accessed April 26, 2016.

  21. US Food and Drug Administration. Bioresearch Monitoring (BIMO) Metrics—FY’13. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RunningClinicalTrials/UCM381797.pdf. Accessed April 26, 2016.

  22. US Food and Drug Administration. Bioresearch Monitoring (BIMO) Metrics—FY’14. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/RunningClinicalTrials/UCM493509.pdf. Accessed April 26, 2016.

  23. US Food and Drug Administration. Bioresearch Monitoring (BIMO) Metrics—FY’15. http://www.fda.gov/downloads/ICECI/EnforcementActions/BioresearchMonitoring/UCM133773.pdf. Accessed April 26, 2016.

  24. US Food and Drug Administration. FDA Form 483 Frequently Asked Questions. US Food and Drug Administration. https://www.fda.gov/ICECI/Inspections/ucm256377.htm. Published April 23, 2015. Accessed May 3, 2017.

  25. Bramstedt KA. A study of warning letters issued to researchers by the United States Food and Drug Administration. Clinical Investigative Medicine. 2004;27:129–134.

    PubMed  Google Scholar 

  26. Gogtay NJ, Doshi BM, Kannan S, Thatte U. A study of warning letters issued to researchers and institutional review boards by the United States Food and Drug Administration. Ind J Med Ethics. 2011;8:211–214.

    CAS  Google Scholar 

  27. Shetty YC, Saiyed AA. Analysis of warning leters issued by the US Food and Drug Administration to researchers, institutional review boards and sponsors: a retrospective study. J Med Ethics. 2014;41:398–403.

    Article  Google Scholar 

  28. Knowlton JA, Wan JY. An analysis of United States Food and Drug Administration Warning Letters Issued to Clinical Investigators from 1996 through 2011. J Clin Res Bioethics. 2011;2:122.

    Article  Google Scholar 

  29. Wilson JM. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mole Genet Metab. 2009;96:151–157.

    Article  CAS  Google Scholar 

  30. Lieu CH, Sorkin A, Messersmitz WA. Right to try? J Clin Oncol. 2015;33:1518–1518.

    Article  Google Scholar 

  31. US Food and Drug Administration. Inspection Citations. US Food and Drug Administration: https://www.fda.gov/ICECI/Inspections/ucm346077.htm. Published April 20, 2017. Accessed April 30, 2017.

  32. US Food and Drug Administration. FY 2006 Inspections Citations. https://www.fda.gov/downloads/ICECI/Inspections/UCM346080.xlsx. Accessed October 25, 2016.

  33. US Food and Drug Administration. FY 2007 Inspections Citations. https://www.fda.gov/downloads/ICECI/Inspections/UCM346082.xlsx. Accessed October 25, 2016.

  34. US Food and Drug Administration. FY 2008 Inspections Citations. https://www.fda.gov/downloads/ICECI/Inspections/UCM346084.xlsx. Accessed October 25, 2016.

  35. US Food and Drug Administration. FY 2009 Inspections Citations. https://www.fda.gov/downloads/ICECI/Inspections/UCM346086.xlsx. Accessed October 25, 2016.

  36. US Food and Drug Administration. FY 2010 Inspections Citations. https://www.fda.gov/downloads/ICECI/Inspections/UCM346088.xlsx. Accessed October 25, 2016.

  37. US Food and Drug Administration. FY 2011 Inspections Citations. https://www.fda.gov/downloads/ICECI/Inspections/UCM346090.xlsx. Accessed October 25, 2016.

  38. US Food and Drug Administration. FY 2012 Inspections Citations. https://www.fda.gov/downloads/ICECI/Inspections/UCM346092.xlsx. Accessed October 25, 2016.

  39. US Food and Drug Administration. FY 2013 Inspections Citations. https://www.fda.gov/downloads/ICECI/Inspections/UCM518820.xlsx. Accessed October 25, 2016.

  40. US Food and Drug Administration. FY 2014 Inspections Citations. https://www.fda.gov/downloads/ICECI/Inspections/UCM518823.xlsx. Accessed October 25, 2016.

  41. US Food and Drug Administration. FY 2015 Inspections Citations. https://www.fda.gov/downloads/ICECI/Inspections/UCM518843.xlsx. Accessed October 25, 2016.

  42. US Food and Drug Administration. CFR — Code of Federal Regulation Title 21. US Food and Drug Administration: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.32. Published September 21, 2016. Accessed May 5, 2017.

  43. US Food and Drug Administration. Investigational Operations Manual. US Food and Drug Administration: https://www.fda.gov/ICECI/inspections/IOM/default.htm. Published April 5, 2017. Accessed May 4, 2017.

  44. US Food and Drug Administration. Inspectional Observations and Citations: A Short Description of Citations. US Food and Drug Administration: http://www.fda.gov/ICECI/Inspections/ucm250729.htm. Published April 23, 2015. Accessed May 3, 2017.

  45. US Food and Drug Administration. FDA Program Alignment Bioresearch Monitoring Program FY2016 Action Plan. US Food and Drug Administration: https://www.fda.gov/AboutFDA/CentersOffices/ucm477078.htm. Published January 4, 2016. Accessed May 6, 2017.

Download references

Author information

Authors and Affiliations

  1. US Food and Drug Administration, 15100 NW 67th Avenue, Suite 400, Miami Lakes, FL, 33014, USA

    Craig A. Garmendia MS

  2. Department of Epidemiology, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL, USA

    Craig A. Garmendia MS

  3. Department of Biostatistics, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL, USA

    Katrina Epnere MPH & Neera Bhansali PhD

Authors
  1. Craig A. Garmendia MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katrina Epnere MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Neera Bhansali PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Craig A. Garmendia MS.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garmendia, C.A., Epnere, K. & Bhansali, N. Research Deviations in FDA-Regulated Clinical Trials: A Cross-Sectional Analysis of FDA Inspection Citations. Ther Innov Regul Sci 52, 579–591 (2018). https://doi.org/10.1177/2168479017751405

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479017751405

Keywords

Search

Navigation